Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 212

1.

Deep sequencing across germline genome-wide association study signals relating to breast cancer events in women receiving aromatase inhibitors for adjuvant therapy of early breast cancer.

Ingle JN, Kalari KR, Momozawa Y, Kubo M, Furukawa Y, Shepherd LE, Ellis MJ, Goss PE, Barman P, Carlson EE, Sinnwell JP, Tang X, Goetz MP, Chen BE, Cairns J, Weinshilboum RM, Wang L.

Pharmacogenet Genomics. 2019 Oct;29(8):183-191. doi: 10.1097/FPC.0000000000000382.

PMID:
31211741
2.

Symptom Assessment and Early Access to Supportive and Palliative Care for Patients With Advanced Solid Tumors in Mexico.

Alcalde-Castro MJ, Soto-Perez-de-Celis E, Covarrubias-Gómez A, Sánchez-Román S, Quiróz-Friedman P, Navarro-Lara Á, Ramos-Lopez WA, Moreno-García ML, Contreras-Garduño S, Perez-Montessoro V, Goss PE, Chávarri-Guerra Y.

J Palliat Care. 2019 Mar 24:825859719834920. doi: 10.1177/0825859719834920. [Epub ahead of print]

PMID:
30907241
3.

Patient Navigation to Enhance Access to Care for Underserved Patients with a Suspicion or Diagnosis of Cancer.

Chavarri-Guerra Y, Soto-Perez-de-Celis E, Ramos-López W, San Miguel de Majors SL, Sanchez-Gonzalez J, Ahumada-Tamayo S, Viramontes-Aguilar L, Sanchez-Gutierrez O, Davila-Davila B, Rojo-Castillo P, Perez-Montessoro V, Bukowski A, Goss PE.

Oncologist. 2019 Sep;24(9):1195-1200. doi: 10.1634/theoncologist.2018-0133. Epub 2018 Nov 29.

PMID:
30498134
4.

Endometrial Cancer in Brazil: Preparing for the Rising Incidence.

Paulino E, Nogueira-Rodrigues A, Goss PE, Faroni L, Guitmann G, Strasser-Weippl K, Bukowski A.

Rev Bras Ginecol Obstet. 2018 Oct;40(10):577-579. doi: 10.1055/s-0038-1673644. Epub 2018 Oct 23.

5.

Discrepancy in risk assessment of hormone receptor positive early-stage breast cancer patients using breast cancer index and recurrence score.

Jerevall PL, Brock J, Palazzo J, Wieczorek T, Misialek M, Guidi AJ, Wu Y, Erlander MG, Zhang Y, Schnabel CA, Goss PE, Horick N, Sgroi DC.

Breast Cancer Res Treat. 2019 Jan;173(2):375-383. doi: 10.1007/s10549-018-5013-6. Epub 2018 Oct 22.

PMID:
30350269
6.

Disparities in Breast, Lung, and Cervical Cancer Trials Worldwide.

Ramaswami R, Paulino E, Barrichello A, Nogueira-Rodrigues A, Bukowski A, St Louis J, Goss PE.

J Glob Oncol. 2018 Sep;4:1-11. doi: 10.1200/JGO.17.00226.

7.

TCL1A, a Novel Transcription Factor and a Coregulator of Nuclear Factor κB p65: Single Nucleotide Polymorphism and Estrogen Dependence.

Ho MF, Lummertz da Rocha E, Zhang C, Ingle JN, Goss PE, Shepherd LE, Kubo M, Wang L, Li H, Weinshilboum RM.

J Pharmacol Exp Ther. 2018 Jun;365(3):700-710. doi: 10.1124/jpet.118.247718. Epub 2018 Mar 28.

8.

Effects of Celecoxib and Low-dose Aspirin on Outcomes in Adjuvant Aromatase Inhibitor-Treated Patients: CCTG MA.27.

Strasser-Weippl K, Higgins MJ, Chapman JW, Ingle JN, Sledge GW, Budd GT, Ellis MJ, Pritchard KI, Clemons MJ, Badovinac-Crnjevic T, Han L, Gelmon KA, Rabaglio M, Elliott C, Shepherd LE, Goss PE.

J Natl Cancer Inst. 2018 Sep 1;110(9):1003-1008. doi: 10.1093/jnci/djy017.

9.

Patient-reported predictors of early treatment discontinuation: treatment-related symptoms and health-related quality of life among postmenopausal women with primary breast cancer randomized to anastrozole or exemestane on NCIC Clinical Trials Group (CCTG) MA.27 (E1Z03).

Wagner LI, Zhao F, Goss PE, Chapman JW, Shepherd LE, Whelan TJ, Mattar BI, Bufill JA, Schultz WC, LaFrancis IE, Nagargoje GG, Vemuri R, Nikcevich DA, Sledge GW, Cella D.

Breast Cancer Res Treat. 2018 Jun;169(3):537-548. doi: 10.1007/s10549-018-4713-2. Epub 2018 Feb 17.

10.

Quality of Life From Canadian Cancer Trials Group MA.17R: A Randomized Trial of Extending Adjuvant Letrozole to 10 Years.

Lemieux J, Brundage MD, Parulekar WR, Goss PE, Ingle JN, Pritchard KI, Celano P, Muss H, Gralow J, Strasser-Weippl K, Whelan K, Tu D, Whelan TJ.

J Clin Oncol. 2018 Feb 20;36(6):563-571. doi: 10.1200/JCO.2017.75.7500. Epub 2018 Jan 12. Erratum in: J Clin Oncol. 2018 May 20;36(15):1540.

11.

Outcomes in women with invasive ductal or invasive lobular early stage breast cancer treated with anastrozole or exemestane in CCTG (NCIC CTG) MA.27.

Strasser-Weippl K, Sudan G, Ramjeesingh R, Shepherd LE, O'Shaughnessy J, Parulekar WR, Liedke PER, Chen BE, Goss PE.

Eur J Cancer. 2018 Feb;90:19-25. doi: 10.1016/j.ejca.2017.11.014. Epub 2017 Dec 20.

PMID:
29274617
12.

Expressed Gene Fusions as Frequent Drivers of Poor Outcomes in Hormone Receptor-Positive Breast Cancer.

Matissek KJ, Onozato ML, Sun S, Zheng Z, Schultz A, Lee J, Patel K, Jerevall PL, Saladi SV, Macleay A, Tavallai M, Badovinac-Crnjevic T, Barrios C, Beşe N, Chan A, Chavarri-Guerra Y, Debiasi M, Demirdögen E, Egeli Ü, Gökgöz S, Gomez H, Liedke P, Tasdelen I, Tolunay S, Werutsky G, St Louis J, Horick N, Finkelstein DM, Le LP, Bardia A, Goss PE, Sgroi DC, Iafrate AJ, Ellisen LW.

Cancer Discov. 2018 Mar;8(3):336-353. doi: 10.1158/2159-8290.CD-17-0535. Epub 2017 Dec 14.

13.

Vitamin D Levels, Vitamin D Receptor Polymorphisms, and Inflammatory Cytokines in Aromatase Inhibitor-Induced Arthralgias: An Analysis of CCTG MA.27.

Niravath P, Chen B, Chapman JW, Agarwal SK, Welschhans RL, Bongartz T, Kalari KR, Shepherd LE, Bartlett J, Pritchard K, Gelmon K, Hilsenbeck SG, Rimawi MF, Osborne CK, Goss PE, Ingle JN.

Clin Breast Cancer. 2018 Feb;18(1):78-87. doi: 10.1016/j.clbc.2017.10.009. Epub 2017 Oct 16.

PMID:
29128193
14.

Patient Navigation to Improve Access to Breast Cancer Care in Brazil.

Bukowski A, Gioia S, Chavarri-Guerra Y, Soto-Perez-de-Celis E, St Louis J, Paulino E, Nogueira-Rodrigues A, Goss PE.

J Glob Oncol. 2016 Nov 30;3(5):433-437. doi: 10.1200/JGO.2016.006726. eCollection 2017 Oct. No abstract available.

15.

Barriers to Primary Debulking Surgery for Advanced Ovarian Cancer in Latin America.

Paulino E, Nogueira Rodrigues A, Strasser-Weippl K, St Louis J, Bukowski A, Goss PE.

Int J Gynecol Cancer. 2017 Oct;27(8):1645-1649. doi: 10.1097/IGC.0000000000001098.

PMID:
28857784
16.

Epidemiology and pathophysiology of pregnancy-associated breast cancer: A review.

Ruiz R, Herrero C, Strasser-Weippl K, Touya D, St Louis J, Bukowski A, Goss PE.

Breast. 2017 Oct;35:136-141. doi: 10.1016/j.breast.2017.07.008. Epub 2017 Jul 18. Review.

PMID:
28732325
17.

End-of-Life Care in Latin America.

Soto-Perez-de-Celis E, Chavarri-Guerra Y, Pastrana T, Ruiz-Mendoza R, Bukowski A, Goss PE.

J Glob Oncol. 2016 Aug 24;3(3):261-270. doi: 10.1200/JGO.2016.005579. eCollection 2017 Jun. Review.

18.

A Rare Presentation of Primary Breast Carcinoma in the Vulva: A Case Report and Literature Review.

Lopes A, St Louis J, Balancin ML, Nogueira-Rodrigues A, Silva LCFF, Paulino E, Sá BS, Bukowski A, Barbosa EM, Costa RLR, Goss PE.

Clin Breast Cancer. 2018 Jun;18(3):e291-e294. doi: 10.1016/j.clbc.2017.06.004. Epub 2017 Jun 23. Review. No abstract available.

PMID:
28709748
19.

TCL1A Single-Nucleotide Polymorphisms and Estrogen-Mediated Toll-Like Receptor-MYD88-Dependent Nuclear Factor-κB Activation: Single-Nucleotide Polymorphism- and Selective Estrogen Receptor Modulator-Dependent Modification of Inflammation and Immune Response.

Ho MF, Ingle JN, Bongartz T, Kalari KR, Goss PE, Shepherd LE, Mushiroda T, Kubo M, Wang L, Weinshilboum RM.

Mol Pharmacol. 2017 Aug;92(2):175-184. doi: 10.1124/mol.117.108340. Epub 2017 Jun 14.

20.

Osteoporosis therapy and outcomes for postmenopausal patients with hormone receptor-positive breast cancer: NCIC CTG MA.27.

Lipton A, Chapman JW, Leitzel K, Garg A, Pritchard KI, Ingle JN, Budd GT, Ellis MJ, Sledge GW, Rabaglio M, Han L, Elliott CR, Shepherd LE, Goss PE, Ali SM.

Cancer. 2017 Jul 1;123(13):2444-2451. doi: 10.1002/cncr.30682. Epub 2017 May 2.

21.

An alert to Latin America: Current human papillomavirus vaccination trends highlight key barriers to successful implementation.

Nogueira-Rodrigues A, Bukowski A, Paulino E, St Louis J, Barrichello A, Sternberg C, Gifoni MAC, Luciani S, Goss PE.

Cancer. 2017 Jun 15;123(12):2193-2199. doi: 10.1002/cncr.30647. Epub 2017 Apr 25. No abstract available.

22.

Impact of baseline BMI and weight change in CCTG adjuvant breast cancer trials.

Yerushalmi R, Dong B, Chapman JW, Goss PE, Pollak MN, Burnell MJ, Levine MN, Bramwell VHC, Pritchard KI, Whelan TJ, Ingle JN, Shepherd LE, Parulekar WR, Han L, Ding K, Gelmon KA.

Ann Oncol. 2017 Jul 1;28(7):1560-1568. doi: 10.1093/annonc/mdx152.

23.

Improving access to high-cost cancer drugs in Latin America: Much to be done.

Ruiz R, Strasser-Weippl K, Touya D, Herrero Vincent C, Hernandez-Blanquisett A, St Louis J, Bukowski A, Goss PE.

Cancer. 2017 Apr 15;123(8):1313-1323. doi: 10.1002/cncr.30549. Epub 2017 Feb 9. Review.

24.

Successful Targeted Therapy of Refractory Pediatric ETV6-NTRK3 Fusion-Positive Secretory Breast Carcinoma.

Shukla N, Roberts SS, Baki MO, Mushtaq Q, Goss PE, Park BH, Gundem G, Tian K, Geiger H, Redfield K, Behr G, Benayed R, Zehir A, Hechtman JF, Darnell RB, Papaemmanuil E, Ladanyi M, Ku N, Kung AL, Baselga J, Drilon A, Hyman DM.

JCO Precis Oncol. 2017;2017. doi: 10.1200/PO.17.00034. Epub 2017 Aug 18. No abstract available.

25.

Real world patterns of care in HER2-overexpressing breast cancer: Results of a survey of TEACH clinical trial investigators in 2011.

Chavarri-Guerra Y, St Louis J, Bukowski A, Soto-Perez-de-Celis E, Liedke PER, Symecko H, Moy B, Higgins M, Finkelstein DM, Goss PE.

Breast. 2017 Feb;31:197-201. doi: 10.1016/j.breast.2016.11.014. Epub 2016 Nov 25.

PMID:
27894048
26.

Genetic Polymorphisms in the Long Noncoding RNA MIR2052HG Offer a Pharmacogenomic Basis for the Response of Breast Cancer Patients to Aromatase Inhibitor Therapy.

Ingle JN, Xie F, Ellis MJ, Goss PE, Shepherd LE, Chapman JW, Chen BE, Kubo M, Furukawa Y, Momozawa Y, Stearns V, Pritchard KI, Barman P, Carlson EE, Goetz MP, Weinshilboum RM, Kalari KR, Wang L.

Cancer Res. 2016 Dec 1;76(23):7012-7023. Epub 2016 Oct 10.

27.

Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years.

Goss PE, Ingle JN, Pritchard KI, Robert NJ, Muss H, Gralow J, Gelmon K, Whelan T, Strasser-Weippl K, Rubin S, Sturtz K, Wolff AC, Winer E, Hudis C, Stopeck A, Beck JT, Kaur JS, Whelan K, Tu D, Parulekar WR.

N Engl J Med. 2016 Jul 21;375(3):209-19. doi: 10.1056/NEJMoa1604700. Epub 2016 Jun 5.

28.

The Potential Role of Patient Navigation in Low- and Middle-Income Countries for Patients With Cancer.

Bukowski A, Chávarri-Guerra Y, Goss PE.

JAMA Oncol. 2016 Aug 1;2(8):994-5. doi: 10.1001/jamaoncol.2016.0766. No abstract available.

PMID:
27228333
29.

Relapse-free survival of statistically standardized continuous RT-PCR estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2): NCIC CTG MA.14.

Chapman JA, Sgroi DC, Goss PE, Zarella E, Binns S, Zhang Y, Schnabel CA, Erlander MG, Pritchard KI, Han L, Badovinac-Crnjevic T, Shepherd LE, Pollak MN.

Breast Cancer Res Treat. 2016 May;157(1):101-8. doi: 10.1007/s10549-016-3806-z. Epub 2016 Apr 26.

PMID:
27116182
30.

New onset vasomotor symptoms but not musculoskeletal symptoms associate with clinical outcomes on extended adjuvant letrozole - Analyses from NCIC CTG MA.17.

Liedke PE, Tu D, Shepherd L, Chavarri-Guerra Y, Pritchard KI, Stearns V, Goss PE.

Breast. 2016 Jun;27:99-104. doi: 10.1016/j.breast.2016.02.010. Epub 2016 Apr 5.

PMID:
27058233
31.

Competing risks of death in women treated with adjuvant aromatase inhibitors for early breast cancer on NCIC CTG MA.27.

Chapman JA, Shepherd LE, Ingle JN, Muss HB, Pritchard KI, Gelmon KA, Whelan TJ, Elliott C, Goss PE.

Breast Cancer Res Treat. 2016 Apr;156(2):343-9. doi: 10.1007/s10549-016-3761-8. Epub 2016 Mar 23.

32.

Current Status and Future Projections of Breast Cancer in Asia.

Fan L, Goss PE, Strasser-Weippl K.

Breast Care (Basel). 2015 Dec;10(6):372-8. doi: 10.1159/000441818. Epub 2015 Dec 15. Review.

33.

Prognostic and predictive effects of diabetes, hypertension, and coronary artery disease among women on extended adjuvant letrozole: NCIC CTG MA.17.

Goodwin RA, Jamal R, Booth CM, Goss PE, Eisenhauer EA, Tu D, Shepherd LE.

Eur J Cancer. 2016 May;58:97-103. doi: 10.1016/j.ejca.2016.01.014. Epub 2016 Mar 14.

PMID:
26986765
34.

Estrogen, SNP-Dependent Chemokine Expression and Selective Estrogen Receptor Modulator Regulation.

Ho MF, Bongartz T, Liu M, Kalari KR, Goss PE, Shepherd LE, Goetz MP, Kubo M, Ingle JN, Wang L, Weinshilboum RM.

Mol Endocrinol. 2016 Mar;30(3):382-98. doi: 10.1210/me.2015-1267. Epub 2016 Feb 11.

35.

Identification of early breast cancer patient cohorts who may benefit from lapatinib therapy.

Strasser-Weippl K, Horick N, Smith IE, O'Shaughnessy J, Ejlertsen B, Boyle F, Buzdar AU, Fumoleau P, Gradishar W, Martin M, Moy B, Piccart-Gebhart M, Pritchard KI, Lindquist D, Rappold E, Finkelstein DM, Goss PE.

Eur J Cancer. 2016 Mar;56:85-92. doi: 10.1016/j.ejca.2015.12.024. Epub 2016 Jan 30.

PMID:
26829011
36.

Assessment of the prognostic and predictive utility of the Breast Cancer Index (BCI): an NCIC CTG MA.14 study.

Sgroi DC, Chapman JA, Badovinac-Crnjevic T, Zarella E, Binns S, Zhang Y, Schnabel CA, Erlander MG, Pritchard KI, Han L, Shepherd LE, Goss PE, Pollak M.

Breast Cancer Res. 2016 Jan 4;18(1):1. doi: 10.1186/s13058-015-0660-6.

37.

Cervical cancer control in Latin America: A call to action.

Bychkovsky BL, Ferreyra ME, Strasser-Weippl K, Herold CI, de Lima Lopes G Jr, Dizon DS, Schmeler KM, Del Carmen M, Randall TC, Nogueira-Rodrigues A, de Carvalho Calabrich AF, St Louis J, Vail CM, Goss PE.

Cancer. 2016 Feb 15;122(4):502-14. doi: 10.1002/cncr.29813. Epub 2015 Dec 15. Review.

38.

Progress and remaining challenges for cancer control in Latin America and the Caribbean.

Strasser-Weippl K, Chavarri-Guerra Y, Villarreal-Garza C, Bychkovsky BL, Debiasi M, Liedke PE, Soto-Perez-de-Celis E, Dizon D, Cazap E, de Lima Lopes G Jr, Touya D, Nunes JS, St Louis J, Vail C, Bukowski A, Ramos-Elias P, Unger-Saldaña K, Brandao DF, Ferreyra ME, Luciani S, Nogueira-Rodrigues A, de Carvalho Calabrich AF, Del Carmen MG, Rauh-Hain JA, Schmeler K, Sala R, Goss PE.

Lancet Oncol. 2015 Oct;16(14):1405-38. doi: 10.1016/S1470-2045(15)00218-1. Review.

PMID:
26522157
39.

Prolactin and breast cancer: The need to avoid undertreatment of serious psychiatric illnesses in breast cancer patients: A review.

Froes Brandao D, Strasser-Weippl K, Goss PE.

Cancer. 2016 Jan 15;122(2):184-8. doi: 10.1002/cncr.29714. Epub 2015 Oct 12. Review.

40.

Rash in lapatinib-treated patients is not associated with human leukocyte antigen polymorphisms.

Parham LR, Briley LP, King KS, Byrne J, Rappold E, Goss PE, Spraggs CF.

Pharmacogenomics. 2015;16(11):1227-9. doi: 10.2217/pgs.15.69. Epub 2015 Aug 12.

PMID:
26265235
41.

Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy.

Strasser-Weippl K, Horick N, Smith IE, O'Shaughnessy J, Ejlertsen B, Boyle F, Buzdar AU, Fumoleau P, Gradishar W, Martin M, Moy B, Piccart-Gebhart M, Pritchard KI, Lindquist D, Rappold E, Finkelstein DM, Goss PE.

Breast Cancer Res. 2015 Apr 16;17:56. doi: 10.1186/s13058-015-0568-1.

42.

TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer.

Isakoff SJ, Mayer EL, He L, Traina TA, Carey LA, Krag KJ, Rugo HS, Liu MC, Stearns V, Come SE, Timms KM, Hartman AR, Borger DR, Finkelstein DM, Garber JE, Ryan PD, Winer EP, Goss PE, Ellisen LW.

J Clin Oncol. 2015 Jun 10;33(17):1902-9. doi: 10.1200/JCO.2014.57.6660. Epub 2015 Apr 6.

43.

Health related quality of life of women in TEACH, a randomised placebo controlled adjuvant trial of lapatinib in early stage Human Epidermal Growth Factor Receptor (HER2) overexpressing breast cancer.

Boyle FM, Smith IE, O'Shaughnessy J, Ejlertsen B, Buzdar AU, Fumoleau P, Gradishar W, Martin M, Moy B, Piccart-Gebhart M, Pritchard KI, Lindquist D, Amonkar M, Huang Y, Rappold E, Williams LS, Wang-Silvanto J, Kaneko T, Finkelstein DM, Goss PE; TEACH Investigators.

Eur J Cancer. 2015 Apr;51(6):685-96. doi: 10.1016/j.ejca.2015.02.005. Epub 2015 Mar 6.

PMID:
25752740
44.

Extending endocrine therapy in women with hormone receptor-positive breast cancer.

Goss PE.

Clin Adv Hematol Oncol. 2015 Jan;13(1):20-2. No abstract available.

PMID:
25679968
45.

Treatment-associated musculoskeletal and vasomotor symptoms and relapse-free survival in the NCIC CTG MA.27 adjuvant breast cancer aromatase inhibitor trial.

Stearns V, Chapman JA, Ma CX, Ellis MJ, Ingle JN, Pritchard KI, Budd GT, Rabaglio M, Sledge GW, Le Maitre A, Kundapur J, Liedke PE, Shepherd LE, Goss PE.

J Clin Oncol. 2015 Jan 20;33(3):265-71. doi: 10.1200/JCO.2014.57.6926. Epub 2014 Dec 15.

46.

Pregnancy-associated breast cancer in women from Shanghai: risk and prognosis.

Strasser-Weippl K, Ramchandani R, Fan L, Li J, Hurlbert M, Finkelstein D, Shao ZM, Goss PE.

Breast Cancer Res Treat. 2015 Jan;149(1):255-61. doi: 10.1007/s10549-014-3219-9. Epub 2014 Dec 14.

47.

Competing risks of death in younger and older postmenopausal breast cancer patients.

Chapman JA, Pritchard KI, Goss PE, Ingle JN, Muss HB, Dent SF, Vandenberg TA, Findlay B, Gelmon KA, Wilson CF, Shepherd LE, Pollak MN.

World J Clin Oncol. 2014 Dec 10;5(5):1088-96. doi: 10.5306/wjco.v5.i5.1088.

48.

Drug withdrawal in women with progressive metastatic breast cancer while on aromatase inhibitor therapy.

Chavarri-Guerra Y, Higgins MJ, Szymonifka J, Cigler T, Liedke P, Partridge A, Ligibel J, Come SE, Finkelstein D, Ryan PD, Goss PE.

Br J Cancer. 2014 Nov 25;111(11):2046-50. doi: 10.1038/bjc.2014.502. Epub 2014 Sep 18.

49.

Access to care issues adversely affect breast cancer patients in Mexico: oncologists' perspective.

Chavarri-Guerra Y, St Louis J, Liedke PE, Symecko H, Villarreal-Garza C, Mohar A, Finkelstein DM, Goss PE.

BMC Cancer. 2014 Sep 9;14:658. doi: 10.1186/1471-2407-14-658.

50.

Reply to P. Niravath et Al.

Maunsell E, Chlebowski RT, Ingle JN, Richardson H, Goss PE.

J Clin Oncol. 2014 Nov 20;32(33):3780-1. doi: 10.1200/JCO.2014.57.9235. Epub 2014 Aug 25. No abstract available.

PMID:
25154825

Supplemental Content

Support Center